| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific... |
| 23 Sep 2026 |
8-K: Other Events
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage... |
| 20 Jul 2026 |
8-K: Regulation FD Disclosure
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 |
| 20 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter agreement (this “Agreement”) is intended to confirm our mutual agreement with respect to your continued employment with Armata Pharmaceuticals, Inc. (the “Company”) from and after the date hereof. |
| 14 Jul 2026 |
Form 4: Birx Deborah, Director
Gave up 14,041 shares to cover exercise price or tax ($59.8K) |
| 13 Jul 2026 |
8-K: Regulation FD Disclosure
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia |
| 13 Jul 2026 | FORM S-8 |
| 24 Jun 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On June 24, 2026, the Board appointed Dr. Gilmer to serve on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as of June 24, 2026. |
| 23 Jun 2026 |
8-K: Other Events
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annua... |
| 13 May 2026 | SCHEDULE 13D/A |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Credit and Security Agreement, dated as of May 12, 2026, by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto (togethe... |
| 07 May 2026 |
8-K: Regulation FD Disclosure
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development |
| 28 Apr 2026 |
Form 4: Gilmer Daniel B., Director
Granted 51,280 Stock Options (Right to Buy) |
| 28 Apr 2026 |
Form 3: Gilmer Daniel B., Director
No securities owned |
Loading...